Dabigatran Warfarin p-value
Age (years) 73.4±5.5 74.0±6.5 0.60
Sex (male) 26 (52.0%) 28 (54.9%) 0.84
Race (white) 50 (100%) 50 (98.0%) 1.00
Ethnicity (non-Hispanic/Latino) 50 (100%) 51 (100%) 1.00
Hypertension 31 (62.0%) 35 (68.6%) 0.48
Diabetes 16 (32.0%) 22 (44.0%) 0.30
Depression 16 (32.0%) 12 (23.5%) 0.34
Heart failure 11 (22.0%) 8 (16.0%) 0.44
Renal disease 8 (16.0%) 14 (28.0%) 0.15
Atherosclerosis 6 (12.0%) 10 (19.6%) 0.30
CAD 8 (16.0%) 18 (36.0%) 0.02
Prior MI 3 (6.0%) 9 (18.0%) 0.07
Prior revascularization 1 (2.0%) 8 (16.0%) 0.03
Prior stroke 6 (12.0%) 6 (11.8%) 0.97
Prior TIA 4 (8.0%) 4 (8.0%) 1.00
History of vascular disease 3 (6.0%) 5 (10.0%) 0.72
AF type, n=67 0.28
Paroxysmal 27 (81.8%) 32 (94.1%)
Persistent 4 (12.1%) 1 (2.9%)
Long-standing persistent 2 (6.1%) 1 (2.9%)
Prior ablation 5 (10.0%) 4 (8.0%) 1.00
Pacemaker 6 (12.0%) 7 (14.0%) 0.77
Defibrillator 2 (4.0%) 2 (4.0%) 1.00
History of cancer 6 (12.0%) 13 (26.0%) 0.07
Sleep apnea 16 (32.0%) 17 (34.0%) 0.83
BMI (kg/m2) 30.7±9.8 29.3±7.8 0.44
Systolic blood pressure 131.5±16.3 131.6±22.5 0.98
Diastolic blood pressure 78.7±12.2 76.1±16.9 0.38
CHA2DS2-VASc Categories, n=100 0.38
<1 3 (6.0%) 2 (4.0%)
2-4 37 (74.0%) 32 (64.0%)
>5 10 (20.0%) 16 (32.0%)
ATRIA Bleeding Risk Categories, n=74 0.29
<1 19 (51.4%) 15 (40.5%)
2-4 15 (40.5%) 21 (56.8%)
>5 3 (8.1%) 1 (2.7%)
Dabigatran starting dose
75 mg BID 3
150 mg BID 44
Withdrew before start 3